title: Comparison of expression and proliferative effect of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors on human astrocytoma cell lines.
abstract: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic neuropeptide considered to be a potent regulator of astrocytes. It has been reported that PACAP also affects astrocytoma cell properties, but the proliferative effects of this peptide in previous reports were inconsistent. The purpose of this study was to search for correlations between malignant potential, PACAP/PACAP receptor expression, and the proliferative potential of four astrocytoma cell lines (KNS-81, KINGS-1, SF-126, and YH-13). Immunohistochemical observations were performed using astrocyte lineage markers with a view to establishing malignant potential, which is inversely correlated to differentiation status in astrocytoma cells. YH-13 showed the most undifferentiated astrocyte-like status, and was immunopositive to a cancer stem cell marker, CD44. These observations suggest that YH-13 is the most malignant of the astrocytoma cell lines tested. Moreover, the strongest PAC1-R immunoreactivity was observed in YH-13 cells. Using real-time PCR analysis, no significant differences among cell lines were detected with respect to PACAP mRNA, but PAC1-R and VPAC1-R mRNA levels were significantly increased in YH-13 cells compared with the other cell lines. Furthermore, when cell lines were treated with PACAP (10(-11) M) for 3 days, the YH-13 cell line, but not of the other cell lines, exhibited a significantly increased cell number. These results suggest that PACAP receptor expression is correlated with the malignant and proliferative potential of astrocytoma cell lines.
authors.affiliation: Department of Anatomy, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8555, Japan.
authors.forename: Tomoya
authors.initials: T
authors.lastname: Nakamachi
authors.forename: Kouichi
authors.initials: K
authors.lastname: Sugiyama
authors.forename: Jun
authors.initials: J
authors.lastname: Watanabe
authors.forename: Nori
authors.initials: N
authors.lastname: Imai
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kagami
authors.forename: Motohide
authors.initials: M
authors.lastname: Hori
authors.forename: Satoru
authors.initials: S
authors.lastname: Arata
authors.forename: Seiji
authors.initials: S
authors.lastname: Shioda
mesh_terms: D001253:Astrocytes / Q000378:metabolism* / Q000502:physiology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D006801:Humans; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / Q000235:genetics / Q000378:metabolism*; D051238:Receptors, Vasoactive Intestinal Polypeptide, Type I / Q000235:genetics / Q000378:metabolism
chemical_list: D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012333:RNA, Messenger; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; D051238:Receptors, Vasoactive Intestinal Polypeptide, Type I
references.citation: Front Endocrinol (Lausanne). 2013 Oct 16;4:144
references.pmid: 24137157
references.citation: J Mol Neurosci. 2008 Nov;36(1-3):16-25
references.pmid: 18483879
references.citation: J Mol Neurosci. 2008 Nov;36(1-3):286-91
references.pmid: 18491045
references.citation: Biochem Biophys Res Commun. 1989 Oct 16;164(1):567-74
references.pmid: 2803320
references.citation: J Mol Neurosci. 2013 Oct;51(2):503-13
references.pmid: 23900722
references.citation: Cancer Manag Res. 2014 Mar 24;6:149-70
references.pmid: 24711712
references.citation: Cancer Cell. 2010 Dec 14;18(6):655-68
references.pmid: 21156287
references.citation: Neuropeptides. 1996 Oct;30(5):491-6
references.pmid: 8923513
references.citation: Peptides. 1994;15(4):661-5
references.pmid: 7937342
references.citation: J Neurosci. 1992 Jul;12(7):2751-64
references.pmid: 1613556
references.citation: Front Neuroendocrinol. 1995 Jan;16(1):53-88
references.pmid: 7768322
references.citation: J Immunol Methods. 2001 Aug 1;254(1-2):85-98
references.pmid: 11406155
references.citation: Biochem Biophys Res Commun. 1990 Jul 31;170(2):643-8
references.pmid: 2383262
references.citation: Peptides. 2007 Sep;28(9):1753-60
references.pmid: 17655978
references.citation: Ann N Y Acad Sci. 2006 Jul;1070:550-60
references.pmid: 16888224
references.citation: Neurosurgery. 1993 Oct;33(4):627-32
references.pmid: 8232801
references.citation: Brain Res Mol Brain Res. 2003 Jul 4;115(1):10-20
references.pmid: 12824050
references.citation: Kaibogaku Zasshi. 2000 Dec;75(6):487-507
references.pmid: 11197592
references.citation: J Neurochem. 2011 May;117(3):403-11
references.pmid: 21244427
references.citation: J Mol Neurosci. 2012 Nov;48(3):508-17
references.pmid: 22674051
references.citation: Brain Cell Biol. 2006 Jun;35(2-3):159-72
references.pmid: 17957481
references.citation: Acta Neuropathol. 2007 Aug;114(2):97-109
references.pmid: 17618441
references.citation: Peptides. 2007 Sep;28(9):1713-9
references.pmid: 17719696
references.citation: Acta Neurochir (Wien). 1978;42(1-2):5-32
references.pmid: 211808
references.citation: J Mol Neurosci. 2003;21(2):91-102
references.pmid: 14593209
references.citation: No To Shinkei. 1993 Apr;45(4):362-8
references.pmid: 8101449
references.citation: Int J Oncol. 2003 Aug;23(2):353-61
references.pmid: 12851684
references.citation: Acta Neurochir Suppl. 2013;118:55-9
references.pmid: 23564104
references.citation: Brain Res. 1984 Aug;317(2):201-9
references.pmid: 6383523
references.citation: Curr Pharm Des. 2011;17(10):973-84
references.pmid: 21524256
references.citation: J Mol Neurosci. 2011 Jan;43(1):16-21
references.pmid: 20574684